282 related articles for article (PubMed ID: 38408603)
1. Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy.
Chauhan S; Jaiswal S; Jakhmola V; Singh B; Bhattacharya S; Garg M; Sengupta S
Cancer Lett; 2024 Apr; 588():216766. PubMed ID: 38408603
[TBL] [Abstract][Full Text] [Related]
2. An updated review of a novel method for examining P53 mutations in different forms of cancer.
Shomali N; Kamrani A; Nasiri H; Heris JA; Shahabi P; Yousefi M; Mohammadinasab R; Sadeghvand S; Akbari M
Pathol Res Pract; 2023 Aug; 248():154585. PubMed ID: 37302277
[TBL] [Abstract][Full Text] [Related]
3. P53: A Guardian of Immunity Becomes Its Saboteur through Mutation.
Agupitan AD; Neeson P; Williams S; Howitt J; Haupt S; Haupt Y
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32414156
[TBL] [Abstract][Full Text] [Related]
4. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy.
Song B; Yang P; Zhang S
Cancer Commun (Lond); 2024 Mar; 44(3):297-360. PubMed ID: 38311377
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
Cui Y; Guo G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
[TBL] [Abstract][Full Text] [Related]
6. P53 and The Immune Response: 40 Years of Exploration-A Plan for the Future.
Levine AJ
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31952115
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY; Jung J; Kim KM; Lee J; Im YH
Cancer Med; 2023 Jun; 12(11):12438-12451. PubMed ID: 37081749
[TBL] [Abstract][Full Text] [Related]
8. Orchestration of immune response by innate lymphoid cell subtype 2 at various tumor microenvironment, a suitable target for cancer immunotherapy.
Roy R; Das T; Biswas N
Int Rev Immunol; 2024; 43(2):74-82. PubMed ID: 37599626
[TBL] [Abstract][Full Text] [Related]
9. A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development.
Shi D; Jiang P
Front Cell Dev Biol; 2021; 9():762651. PubMed ID: 34733856
[TBL] [Abstract][Full Text] [Related]
10. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA; Yang LV; Abrams SL; Steelman LS; Follo MY; Cocco L; Ratti S; Martelli AM; Augello G; Cervello M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883598
[TBL] [Abstract][Full Text] [Related]
11. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress.
Zhu KL; Su F; Yang JR; Xiao RW; Wu RY; Cao MY; Ling XL; Zhang T
Mol Biol Rep; 2024 Jan; 51(1):205. PubMed ID: 38270700
[TBL] [Abstract][Full Text] [Related]
12. p53, cancer and the immune response.
Blagih J; Buck MD; Vousden KH
J Cell Sci; 2020 Mar; 133(5):. PubMed ID: 32144194
[TBL] [Abstract][Full Text] [Related]
13. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models.
Kenzelmann Broz D; Attardi LD
Carcinogenesis; 2010 Aug; 31(8):1311-8. PubMed ID: 20097732
[TBL] [Abstract][Full Text] [Related]
14. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity.
Zhou X; Singh M; Sanz Santos G; Guerlavais V; Carvajal LA; Aivado M; Zhan Y; Oliveira MMS; Westerberg LS; Annis DA; Johnsen JI; Selivanova G
Cancer Discov; 2021 Dec; 11(12):3090-3105. PubMed ID: 34230007
[TBL] [Abstract][Full Text] [Related]
16. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
17. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
18. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53-a potential player in shaping the tumor-stroma crosstalk.
Stein Y; Aloni-Grinstein R; Rotter V
J Mol Cell Biol; 2019 Jul; 11(7):600-604. PubMed ID: 31318969
[TBL] [Abstract][Full Text] [Related]
20. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
